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Background: B-type natriuretic peptide (BNP) is a predictor of death in patients with lung disease.
We hypothesised that in patients with lung disease, BNP and N-terminal-pro-B-type natriuretic
peptide (NT-proBNP) could predict a peak VO2< 15 ml/kg/min,which is the proposed cut-off indi-
cating an increased risk of perioperative complications during lung resection surgery.
Methods: BNP and NT-proBNP were measured in 85 patients with a variety of pulmonary patholo-
gies undergoing cardiopulmonary exercise testing and fulfilling criteria for appropriate effort.
Results: BNP [69 (42e270) vs. 33 (15e65) pg/ml; pZ 0.001] and NT-proBNP [290 (129e1075) vs.
65 (21e129) pg/ml; p< 0.001] were higher in patients with peak VO2< 15 ml/kg/min (nZ 27) as
compared to those with peak VO2 15 ml/kg/min (nZ 58). Apart from the forced expiratory
volume within the first second (FEV1), body mass index (BMI), diabetes, and the alveolo-arterial
oxygen pressure difference [D(A-a)O2; only in the BNP model], BNP or NT-proBNP respectively
were independent predictors of peak VO2< 15 ml/kg/min. The areas under the receiver-
operator-characteristics curve (AUC) for BNP and NT-proBNP to predict a peak VO2< 15 ml/kg/
min were 0.73 and 0.80 respectively. A five-item (BNP) or four-item (NT-proBNP) score including
BMI, FEV1, diabetes, D(A-a)O2, and BNP/NT-proBNP had an AUC of 0.87 and 0.88 respectively for
the prediction of peak VO2< 15 ml/kg/min.
Conclusions: In patients with lung disease, BNP or NT-proBNP is independently associated with
low peak VO2. A simple score based on spirometry, blood gases and BNP or NT-proBNP has a high
accuracy for the prediction of a peak VO2< 15 ml/kg/min.
ª 2009 Elsevier Ltd. All rights reserved.8532 1111; fax: þ61 3 8532 1100.
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In patients with lung disease, cardiopulmonary exercise
testing (CPET) with measurement of peak oxygen
consumption (peak VO2) has a broad range of applications.
1
In patients with chronic obstructive pulmonary disease
(COPD), peak VO2 serves as an objective measure of exer-
cise capacity and to assess the effect of specific therapies.1
Furthermore, peak VO2 is a strong predictor of perioper-
ative complications in patients undergoing lung resection
for cancer.2 The current American College of Chest Physi-
cians guidelines on the physiologic evaluation of patients
with lung cancer being considered for surgery3 recommend
CPET for patients who based on the forced expiratory
volume within the first second (FEV1) and diffusion capacity
cannot be considered as low risk. According to these
guidelines, a peak VO2< 15 ml/kg/min indicates an
increased risk.3 The appropriateness of this cut-off has
recently been confirmed in a meta-analysis.2
However, CPET is a demanding, time-consuming and not
broadly applied technique.4 As peak VO2 may be signifi-
cantly overestimated by the maximal workload in a stan-
dard treadmill or bicycle exercise test,5 particularly in
patients with low exercise capacity, such a test is often an
insufficient alternative to CPET. Thus, an easily available
biomarker reflecting peak VO2 would be very useful in
clinical practice. In patients with heart failure, B-type
natriuretic peptide (BNP)6 and N-terminal-pro-B-type
natriuretic peptide (NT-proBNP)7 have a moderate to good
accuracy for the identification of a peak VO2< 14 ml/kg/
min, which is an important prognostic cut-off in patients
considered for cardiac transplantation.8 Similar data for
patients with pulmonary disease are not available.
However, BNP has been found to be an independent
predictor of survival in patients with various lung diseases.9
This relationship was mainly due to the ability of BNP to
identify the presence of pulmonary hypertension in these
patients.9 We therefore hypothesised that BNP and NT-
proBNP might be useful to identify patients with pulmonary
disease and significantly impaired peak VO2.
Methods
Study population
From May 2004 to June 2005, 104 consecutive patients with
lung disease referred for CPET for the evaluation of exer-
cise capacity were eligible. Nineteen patients not fulfilling
the criteria for appropriate effort (see below) were
secondarily excluded, leaving 85 patients for the present
analysis. Otherwise, there were no exclusion criteria. The
study was approved by the local ethics committee. Written
informed consent was obtained from all participating
patients.
CPET procedures
Spirometry (Jaeger, Wuerzburg, Germany) was performed
before CPET according to the American Thoracic Society
guidelines.10 Thereafter, patients were seated on the exer-
cise bike (Jaeger, Wuerzburg, Germany) and underwentsymptom-limited upright bicycle exercise using ramp
protocols with continuous monitoring of the electrocardio-
gram throughout the test. Standard criteria for test termi-
nation were applied.4 Expired gases were acquired
continuously, and oxygen uptake and carbon dioxide output
were expressed as the highest 10 s average values obtained
during the last 30 s of the test. Calibration of the air flow
system was performed before each test with a 3-liter
syringe, and calibration of the gas sensors was performed
daily. The respiratory exchange ratio (RER), defined as the
carbon dioxide output divided by the oxygen uptake was
determined throughout the test. Arterial bloodwas obtained
at rest and at peak exercise from a radial or brachial artery
and immediately analysed. Maximal or near maximal effort
was assumed if at least one of the following criteria was
fulfilled: (1) peak heart rate> 80% predicted, (2) RER> 1.2,
(3) lactate at peak exercise> 4.0 mmol/l, or (4) difference
between base excess at rest and peak exercise
<2.5 mmol/l.11
BNP and NT-proBNP measurement
A specimen of venous blood was drawn immediately
before the test in the seated position from a catheter
previously inserted into an antecubital vein. Samples were
collected in plastic tubes containing ethylene-diamine-
tetra-acetate, placed on ice, and centrifuged at 3000 g.
Plasma samples were immediately analysed for BNP and
NT-proBNP by a laboratory technician who was blinded to
the patients characteristics and CPET results. BNP
concentration was determined using the commercially
available AxSYM BNP assay (Abbott Laboratories, Zug,
Switzerland),12 and NT-proBNP was measured using the
commercially available Elecsys proBNP assay (Roche
Diagnostics, Basel, Switzerland).13
Statistical analysis
Data were expressed as numbers and percentages,
mean standard deviation, and median (interquartile range)
unless otherwise indicated. Comparisons between patients
with peak VO2< 15 ml/kg/min and 15 ml/kg/min were
performed using chi-square, unpaired t-tests, or Manne
Whitney-U tests as appropriate. Correlations between
parameters of interest were assessed using Spearman
correlation coefficients. Multivariate logistic regression was
performed to identify independent predictors of a peak
VO2< 15 ml/kg/min. All parameters available before the
exercise test (Tables 1 and 2) as well as BNP (log10-trans-
formed values, first model) or NT-proBNP (log10-trans-
formed values, second model) were tested. Parameters
with a p value <0.1 in the univariate analysis were entered
in the multivariate analysis. Receiver-operator-character-
istics (ROC) curves were constructed to determine the
accuracy of the resulting multivariate predictors for the
prediction of a peak VO2< 15 ml/kg/min. AUC were
compared using the method of DeLong et al.14 A p value
<0.05 was considered statistically significant. Analysis was
performed using commercially available software packages
(SPSS/PC, version 15.0, SPSS Inc, Chicago, Illinois, USA, and
Analyse-it V2.04, Leeds, UK).
Table 1 Baseline characteristics of patients with peak oxygen consumption (peak VO2) <15 ml/kg/min as compared to those
with peak VO2 15 ml/kg/min.
Peak VO2< 15 ml/kg/min (nZ 27) Peak VO2 15 ml/kg/min (nZ 58) p value
Age (years) 62.3 11.2 54.4 15.1 0.02
Male gender 14 (52%) 36 (62%) 0.37
Body mass index (kg/m2) 27.3 5.3 25.4 4.3 0.09
COPD 16 (59%) 23 (40%) 0.09
Asthma bronchiale 2 (7%) 11 (19%) 0.17
Other pulmonary diseasea 9 (33%) 24 (41%) 0.48
Lung cancer 12 (44%) 21 (36%) 0.47
Other medical history
Coronary artery disease 11 (41%) 4 (7%) <0.001
Previous myocardial infarction 7 (26%) 3 (5%) 0.006
Other heart disease 1 (4%) 7 (12%) 0.22
Diabetes mellitus 5 (19%) 2 (3%) 0.02
Current smoking 6 (22%) 19 (33%) 0.32
Previous smoking 15 (56%) 25 (43%) 0.28
Medication
Inhaled corticosteroids 7 (26%) 21 (36%) 0.35
Inhaled b-2-mimetics 11 (41%) 22 (38%) 0.81
Betablockers 11 (41%) 5 (9%) <0.001
ACEI/ARB 9 (33%) 6 (10%) 0.01
Diuretic 8 (30%) 5 (9%) 0.01
Aspirin 11 (41%) 4 (7%) <0.001
Statin 11 (41%) 8 (14%) 0.005
Data are given as numbers and percentages or mean standard deviation.
COPD: chronic obstructive pulmonary disease; ACEI/ARB: angiotensin converting enzyme inhibitor or angiotensin receptor blocker.
a For details see text.
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Patients
Among the 85 patients, 39 (46%) had COPD, 13 (15%) had
asthma, and 33 (39%) had other lung diseases, includingTable 2 Measurements at rest in patients with peak oxygen co
with peak VO2 15 ml/kg/min.
Peak VO2< 15 ml/kg/min (
Heart rate (bpm) 82 17
Systolic blood pressure (mmHg) 132 24
Diastolic blood pressure (mmHg) 87 15
Creatinine clearance (ml/min) 89 31
Left ventricular
ejection fraction (%)
60 (44e62), nZ 16
Respiratory rate (1/min) 20 5
FEV1 (l) 1.75 0.70
FEV1/FVC 0.65 0.13
Haemoglobin (g/dl) 13.8 2.3
PaO2 (mmHg) 74.9 15.3
Arterial oxygen saturation (%) 95 (91e96)
PaCO2 (mmHg) 34.6 4.9
D(A-a)O2 (mmHg) 31.4 14.5
Lactate (mmol/l) 1.2 (1.0e1.9)
pH 7.44 0.03
Data are given as mean standard deviation or median (interquartile
FEV1: forced expiratory volume within the first second; FVC: forced vit
arterial carbon dioxide; D(A-a)O2: alveolo-arterial oxygen pressure disarcoidosis (nZ 3), primary pulmonary hypertension (nZ 2),
interstitial pneumopathy (nZ 6), alveolitis (nZ 1), bronchi-
ectasis (nZ 2), unclear lung diseases (nZ 2), or lung cancer/
mesothelioma (nZ 17). Fifteen patients also had lung cancer
in the presence of another pulmonary disease. The charac-
teristics of patients achieving a peak VO2< 15 ml/kg/minnsumption (peak VO2) <15 ml/kg/min as compared to those
nZ 27) Peak VO2 15 ml/kg/min (nZ 58) p value
84 14 0.60
125 15 0.11
85 10 0.62
97 34 0.33
60 (60e65), nZ 24 0.08
19 6 0.71
2.39 0.83 0.001
0.68 0.12 0.27
14.3 1.8 0.24
81.7 11.9 0.03
95 (94e96) 0.15
35.1 4.4 0.61
22.4 12.4 0.004
1.0 (0.8e1.4) 0.10
7.44 0.03 0.99
range).
al capacity; PaO2: pressure of arterial oxygen; PaCO2: pressure of
fference.
1340 M.T. Maeder et al.(nZ 27) vs. 15 ml/kg/min (nZ 58) are presented in Table
1. Patients with a peak VO2< 15 ml/kg/min were older, ten-
ded to be more overweight and to be more likely to have
COPD, were more likely to have concomitant coronary artery
disease and diabetes, and were more likely to take cardiac
medication.
Measurements at rest
In Table 2, the two groups are compared with respect to
measurements available before the exercise test. Left
ventricular ejection fraction (data available only in a subset
of patients) tended to be lower, FEV1 and arterial oxygen
pressure (PaO2) were lower, and the alveolo-arterial oxygen
pressure difference [D(A-a)O2] was higher in patients with
a peak VO2< 15 ml/kg/min as compared to those with
a peak VO2 15 ml/kg/min.
CPET
In Table 3, CPET data are presented. By definition, exercise
capacity expressed as body weight-indexed maximal work-
load, body weight-indexed peak VO2, and percent predicted
peak VO2 was lower in patients with peak VO2< 15 ml/kg/
min as compared to those with peak VO2 15 ml/kg/min.
Peak heart rate, peak respiratory rate, peak ventilation, and
PaO2were lower, and D(A-a)O2 at peak exercisewas higher in
patients with peak VO2< 15 ml/kg/min as compared to
those with peak VO2 15 ml/kg/min.Table 3 Measurements at peak exercise in patients with peak ox
those with peak VO2 15 ml/kg/min.
Peak VO2< 15 ml/kg/min (nZ
Duration of exercise (min) 4.8 (4.2e5.8)
Peak heart rate (bpm) 119 20
% Predicted heart rate (%) 76 15
Systolic blood
pressure (mmHg)
177 30
Diastolic blood
pressure (mmHg)
94 18
Respiratory rate (1/min) 32 7
Maximal workload (W/kg) 1.06 0.23
Peak VO2 (ml/kg/min) 12.3 1.7
% Predicted peak VO2 (%) 54 14
Respiratory exchange ratio 1.18 0.16
Minute ventilation (l/min) 44.9 14.5
Peak VE/VCO2 41.9 11.5
PaO2 (mmHg) 78.0 25.8
Arterial oxygen
saturation (%)
91 (86e96)
PaCO2 (mmHg) 35.4 6.6
D(A-a)O2 (mmHg) 36.2 23.3
pH 7.39 0.07
Lactate (mmol/l) 4.9 (4.2e5.9)
Data are given as mean standard deviation or median (interquartile
PaO2: pressure of arterial oxygen; PaCO2: pressure of arterial carbonBNP and NT-proBNP levels
Median BNP and NT-proBNP levels in the entire cohort were
43 (18e97) pg/ml and 96 (38e289) pg/ml respectively. As
shown in Fig. 1, BNP and NT-proBNP were significantly higher
in patientswith peak VO2< 15 ml/kg/min as compared those
with peak VO2 15 ml/kg/min.
Relationship between BNP and NT-proBNP
and peak VO2
In Fig. 2, the relationship between peak VO2 and BNP (panel
A) andNT-proBNP (panel B) is visualisedas scatter plots. There
was a moderate inverse correlation between peak VO2 and
both BNP (rZ0.47; panel A) and NT-proBNP (rZ0.59;
panel B). The correlations between peak VO2 and natriuretic
peptidesweresimilar forpatientswithCOPD(BNP: rZ0.46;
pZ 0.003; NT-proBNP: rZ0.52; pZ 0.001) and those with
pulmonary diseases other than COPD (BNP: rZ0.52;
p< 0.001; NT-proBNP: rZ0.61; p< 0.001).
Independent predictors of peak
VO2< 15 ml/kg/min
In the first multivariate logistic regression model, higher
bodymass index (BMI), the presence of diabetes, lower FEV1,
higher D(A-a)O2, and higher BNP were independent predic-
tors of a peak VO2< 15 ml/kg/min (Table 4). In the second
model, BMI, the presence of diabetes, lower FEV1, and higherygen consumption (peak VO2) <15 ml/kg/min as compared to
27) Peak VO2 15 ml/kg/min (nZ 58) p value
6.6 (5.4e7.9) <0.001
148 21 <0.001
89 10 <0.001
186 32 0.20
92 15 0.60
37 8 0.01
1.89 0.61 <0.001
21.6 6.0 <0.001
79 15 <0.001
1.18 0.13 0.79
67.6 23.1 <0.001
37.6 8.9 0.06
89.6 18.1 0.02
95 (93e96) 0.009
35.3 5.2 0.90
25.7 16.4 0.004
7.35 0.05 0.006
6.6 (4.6e8.3) 0.01
range).
dioxide; D(A-a)O2: alveolo-arterial oxygen pressure difference.
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Figure 1 Box plots showing B-type natriuretic peptide (BNP;
panel A) and N-terminal-pro-B-type natriuretic peptide (NT-
proBNP; panel B) in patients with peak oxygen consumption
(peak VO2) <15 ml/kg/min and those with peak VO2 15 ml/
kg/min. The boxes represent medians with interquartile
ranges; the whiskers indicate the 10th and the 90th percentile.
Figure 2 Scatter plots showing the correlation between
B-type natriuretic peptide (BNP; panel A) and N-terminal-pro-
B-type natriuretic peptide (NT-proBNP; panel B) and peak
oxygen consumption. Spearman correlation coefficients are
given. Note the logarithmic scale for BNP and NT-proBNP.
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VO2< 15 ml/kg/min (Table 4).Table 4 Multivariate predictors of peak VO2< 15 ml/kg/
min with either B-type natriuretic peptide (BNP) or N-
terminal-pro-B-type natriuretic peptide (NT-proBNP) in the
logistic regression model.
Odds ratio
(95% confidence interval)
p value
Model 1
Body mass index 1.17 (1.01e1.36) 0.035
Diabetes 32.97 (2.17e501.80) 0.01
FEV1 0.22 (0.08e0.60) 0.003
D(A-a)O2 1.06 (1.01e1.21) 0.02
Log10 BNP 14.24 (2.94e69.08) 0.001
Model 2
Body mass index 1.19 (1.01e1.39) 0.035
Diabetes 34.16 (1.91e609.69) 0.016
FEV1 0.24 (0.09e0.67) 0.006
Log10 NT-proBNP 16.44 (3.92e68.97) <0.001
FEV1: forced expiratory volume within the first second;
D(A-a)O2: alveolo-arterial oxygen pressure difference.Accuracy of BNP and NT-proBNP for the prediction
of a peak VO2< 15 ml/kg/min
In Fig. 3, ROC curves for BNP and NT-proBNP for the
prediction of a peak VO2< 15 ml/kg/min are displayed. The
areas under the curve (AUC) for BNP and NT-proBNP were
0.73 and 0.80 respectively (pZ 0.06 for the comparison of
the two AUC). The optimal BNP cut-off of 36.1 pg/ml had
a sensitivity of 85% and a specificity of 55%, and the optimal
NT-proBNP cut-off of 123.5 pg/ml had a sensitivity of 78%
and a specificity of 74%.
Information on left ventricular ejection fraction (LVEF)
was available in 40 patients. In this subgroup, the AUC for
BNP and NT-proBNP for the prediction of a peak
VO2< 15 ml/kg/min was 0.79 (95% confidence interval
0.65e0.93; pZ 0.002) and 0.85 (95% confidence interval
0.73e0.98; p< 0.001) respectively. In contrast, the corre-
sponding AUC for LVEF was 0.66 (95% confidence interval
0.48e0.84; pZ 0.09). The difference in the AUC for NT-
proBNP and LVEF just failed to reach statistical significance
(pZ 0.06).
Figure 3 Receiver-operator-characteristics (ROC) curves
showing the accuracy of B-type natriuretic peptide (BNP) and
N-terminal-pro-B-type natriuretic peptide (NT-proBNP) for the
prediction of a peak oxygen consumption <15 ml/kg/min. AUC
(95%CI): area under the ROC curve and 95% confidence interval.
1342 M.T. Maeder et al.BNP and NT-proBNP combined with other
parameters for the prediction of a peak
VO2< 15 ml/kg/min
In Table 5, the optimal cut-offs and test characteristics of
all independent pre-test predictors of peak VO2< 15 ml/
kg/min are shown. We constructed a five-item (for BNP)
and a four-item (for NT-proBNP) score for the prediction of
a peak VO2< 15 ml/kg/min based on these parameters. As
shown in Fig. 4A, a five-item score with one score point for
BMI, FEV1, diabetes, D(A-a)O2, and BNP if above/below the
cut-off or present/absent respectively, had an AUC of 0.87
for the prediction of a peak VO2< 15 ml/kg/min. A score of
zero points had a sensitivity and negative predictive value
of 100%. A score of four points (no patient had a score of
five) had a specificity and a positive predictive value of
100%. An analogue four-item score for the NT-proBNP model
had an AUC of 0.88 (Fig. 4B). A score of zero points had
a sensitivity and a negative predictive value of 96%. A score
of three points (no patient had a score of four) had
a specificity and a positive predictive value of 100%.Table 5 Optimal cut-offs and test characteristics of independe
Cut-off Sensitivity (%)
BNP 36.1 pg/ml 85
NT-proBNP 123.5 pg/ml 78
FEV1 1.80 l 63
Body mass index 27.8 kg/m2 52
D(A-a)O2 28 mmHg 63
Diabetes Present 19
PPV: positive predictive value; NPV: negative predictive value.
BNP: B-type natriuretic peptide; NT-proBNP: N-terminal-pro-B-type na
second; D(A-a)O2: alveolo-arterial oxygen pressure difference.BNP and NT-proBNP for the prediction of a peak
VO2< 50% of the predicted value
We also assessed the ability of both markers to predict
a peak VO2< 50% of the predicted value. The latter cut-off
was selected based on the American Thoracic Society/
American College of Chest Physicians statement on CPET,
where a cut-off of 50e60% of the predicted peak VO2 is
proposed as a predictor of higher morbidity and mortality
after lung resection.1 The corresponding AUC for BNP and
NT-proBNP at rest was 0.68 (0.50e0.84; pZ 0.04) and 0.70
(0.56e0.85; pZ 0.01) respectively (pZ 0.45 for the
comparison of the two AUC).
Discussion
The present study evaluating the usefulness of BNP and NT-
proBNP for the prediction of a significantly impaired peak
VO2 among patients with a variety of pulmonary diseases
revealed two new findings. First, BNP and particularly NT-
proBNP were independently associated with a peak
VO2< 15 ml/kg/min. Second, a score combining BNP or NT-
proBNP with other parameters measured at rest and typi-
cally available in these patients had a very high accuracy
for the prediction of a peak VO2< 15 ml/kg/min.
BNP and NT-proBNP are markers of myocardial stretch,
and thereby established tools for the differentiation
between cardiac and non-cardiac dyspnoea.15 Numerous
studies have also evaluated the usefulness of BNP and NT-
proBNP for the diagnosis of a suspected cardiac disease and
assessment of the severity and outcome of an established
cardiac disease respectively.16 In contrast, the applicability
of BNP and NT-proBNP in patients with lung disease was
more or less restricted to the negative predictive value of
these biomarkers for concomitant heart failure.17 Recently
however, the prognostic value of natriuretic peptides in
patients presenting with respiratory disorders has been
recognised.18,19 In patients with community-acquired
pneumonia, BNP is an independent predictor of death and
treatment failure.18 In addition, BNP has been shown to
predict the need for intensive care unit admission in
patients with acute exacerbation of COPD.19 Interestingly,
BNP has been shown to be an independent predictor of
death in stable patients with various advanced lung
diseases, in whom left heart pathologies were excluded.9
In the present study we demonstrated that similarly to
patients with heart failure, BNP and NT-proBNP werent predictors of peak oxygen consumption <15 ml/kg/min.
Specificity (%) NPV (%) PPV (%)
55 89 47
74 88 58
78 82 57
79 78 54
65 79 46
97 72 71
triuretic peptide; FEV1: forced expiratory volume within the first
Figure 4 Panel A: Receiver-operator-characteristics (ROC)
curves showing the accuracy of B-type natriuretic peptide
(BNP), the forced expiratory volume within the first second
(FEV1, plotted as 1/FEV1), and a five-point score (BNP, FEV1,
body mass index, diabetes, alveolo-arterial oxygen pressure
differences) for the prediction of a peak oxygen consumption
(peak VO2) <15 ml/kg/min. For cut-offs refer to the text. AUC
(95%CI): area under the ROC curve and 95% confidence interval.
Panel B: ROC curves showing the accuracy of N-terminal-pro-B-
type natriuretic peptide (NT-proBNP), FEV1 (plotted as 1/
FEV1), and a four-point score (NT-proBNP, FEV1, body mass
index, diabetes) for the prediction of a peak VO2< 15 ml/kg/
min. For cut-offs refer to the text.
BNP/NT-proBNP and peak VO2 in lung disease 1343related to peak VO2 also in patients with lung disease.
Based on the present data we cannot explain the nature of
the association between BNP and NT-proBNP and peak VO2.
However, right ventricular stress due to pulmonary hyper-
tension might play a role. In a cohort of 176 patients with
a variety of lung diseases, Leuchte et al. have shown that
BNP expressed as a ‘‘normalized BNP ratio’’ (i.e., measured
value divided by the age and gender-predicted value) had
an excellent accuracy (AUC 0.91) for the detection of
advanced pulmonary hypertension (mean pulmonary arterypressure >35 mmHg in the presence of a pulmonary capil-
lary wedge pressure <12 mmHg), and that this BNP ratio
was predictive of survival.9 Somewhat contradictory,
another study had shown that NT-proBNP levels in stable
patients with pulmonary disease were not elevated as long
as the mean pulmonary artery pressure did not exceed
40 mmHg.20 Apart from BNP and NT-proBNP release due
to right ventricular stretch it is likely that elevated BNP and
NT-proBNP levels in the present population also reflected
the presence of concomitant left heart disease.
This assumption is supported by the findings of the multi-
variate logistic regression analysis, where BNP and NT-
proBNP turned out as independent predictors of a peak
VO2< 15 ml/kg/min and thereby outperformed any vari-
able reflecting a history of (left-sided) cardiac disease.
Cardiac disease in patients with COPD (50% of the present
population) has a high prevalence. NT-proBNP has been-
previously found to be a predictor of low physical activity in
COPD patients, independent of traditional markers of COPD
severity.21
The correlation coefficients for the relationship between
peak VO2 and natriuretic peptides indicate that BNP and
NT-proBNP explained 22% and 35% respectively of the
variability of peak VO2. Thus, as also illustrated by the AUC
and as expected from our understanding of peak VO2 as
a parameter, which is influenced by the function of several
organ systems, the accuracy of the biomarkers alone is
insufficient for clinical application. We have however
shown that by the combination of BNP and NT-proBNP with
FEV1, which belongs to the basic examinations in patients
with pulmonary diseases and is also required as a first step
in the assessment of the operability of patients considered
for lung resection,3 and other routine measures in these
patients, a score with a very high accuracy for the predic-
tion of a peak VO2< 15 ml/kg/min was obtained. This score
makes sense from a pathophysiological point of view as
BNP/NT-proBNP (cardiac output), FEV1 (ventilation), D(A-
a)O2 (diffusion), BMI (training/metabolic abnormalities),
and diabetes (metabolic abnormalities/microvascular
dysfunction) can be assumed to reflect different factors
contributing to the peak VO2.
Based on these data it is tempting to speculate that the
measurement of BNP and particularly NT-proBNP integrated
into the proposed score might replace CPET in some
patients in the preoperative setting. Of note, the FEV1 cut-
off of 1.80 l makes sense as it lies just between 1.5 l, which
is the cut-off for an increased risk in patients undergoing
pneumonectomy, and 2.0 l, which is the cut-off for an
increased risk in patients undergoing lobectomy.3 None-
theless, we want to stress that we studied a very limited
number of patients, and that the present data can only
serve as a model for the utility of BNP and NT-proBNP in this
setting at the moment. A prospective head-to-head evalu-
ation of CPET and natriuretic peptides for preoperative risk
stratification in patients undergoing lung resection is war-
ranted to confirm the findings of our pilot study.Limitations
We acknowledge that our study has a number of limitations,
which warrant discussion. First, exercise time was shorter
1344 M.T. Maeder et al.than the recommended 8e12 min in more than 75% of the
population, which might have had an impact on the peak
VO2 values obtained. However, the general application of
this recommendation has very recently been challenged in
a study among patients with severe chronic COPD, where
tests with an exercise duration between 4:04 and 8:46 min
revealed similar peak VO2 values.
22 Second, similarly to
healthy people and patients with heart failure, bicycle
exercise has been shown to yield a lower peak VO2 than
treadmill exercise in patients with COPD in a recent
study.23 An earlier study however did not reveal a differ-
ence in peak VO2 in the two test modalities in this pop-
ulation.24 Third, echocardiograms were available only in
a subset of patients. The analysis of the subgroup of
patients with available information on LVEF revealed
however that the AUC for LVEF for the prediction of a peak
VO2< 15 ml/kg/min was not better than for BNP and NT-
proBNP. We acknowledge that echocardiographic parame-
ters other than LVEF such as tissue Doppler measurements25
might have been more suitable to predict peak VO2.
Theoretically, echocardiography would also have allowed
us to test whether BNP and NT-proBNP levels were really
related to pulmonary artery pressure. However, the yield of
echocardiography for the measurement of pulmonary
pressure in patients with advanced pulmonary disease is
generally low. In a cohort of 364 lung transplant candidates,
estimation of systolic pulmonary artery pressure was
possible in only 44% of patients, and the difference
between invasively measured and echocardiographically
estimated systolic pulmonary artery pressures was more
than 10 mmHg in 52% of those with available echo data.26
Fourth, we evaluated only one peak VO2 cut-off. We have
shown that somewhat worse test characteristics were
found for a peak VO2 cut-off expressed as a percentage of
the predicted value, which however is not an unexpected
finding given that BNP and NT-proBNP depend on age. Most
of the prognostic data on peak VO2 are based on absolute
rather than percent predicted values.
Conclusions
In patients with lung disease, BNP and NT-proBNP are
independently associated with a significantly impaired peak
VO2. A score composed of BNP or NT-proBNP, spirometry,
blood gases, and other clinical information has a high
accuracy for the prediction of a severely impaired peak VO2
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